These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
324 related articles for article (PubMed ID: 32371591)
21. Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma. Li Y; Guessous F; Johnson EB; Eberhart CG; Li XN; Shu Q; Fan S; Lal B; Laterra J; Schiff D; Abounader R Lab Invest; 2008 Feb; 88(2):98-111. PubMed ID: 18059365 [TBL] [Abstract][Full Text] [Related]
22. PUMC-MB1 is a novel group 3 medulloblastoma preclinical model, sensitive to PI3K/mTOR dual inhibitor. Wang S; Zhang D; Wang J; Peng X; Sun H; Ji Y; Yang Z; Bian X; Hou Y; Ge M; Liu Y J Neurooncol; 2024 May; 168(1):139-149. PubMed ID: 38662151 [TBL] [Abstract][Full Text] [Related]
23. Targeting c-Myc: JQ1 as a promising option for c-Myc-amplified esophageal squamous cell carcinoma. Wang J; Liu Z; Wang Z; Wang S; Chen Z; Li Z; Zhang M; Zou J; Dong B; Gao J; Shen L Cancer Lett; 2018 Apr; 419():64-74. PubMed ID: 29366803 [TBL] [Abstract][Full Text] [Related]
24. The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition. Craveiro RB; Ehrhardt M; Velz J; Olschewski M; Goetz B; Pietsch T; Dilloo D Oncotarget; 2017 Jul; 8(29):46915-46927. PubMed ID: 28159923 [TBL] [Abstract][Full Text] [Related]
25. mTOR pathway as a potential target in a subset of human medulloblastoma. Pócza T; Sebestyén A; Turányi E; Krenács T; Márk A; Sticz TB; Jakab Z; Hauser P Pathol Oncol Res; 2014 Oct; 20(4):893-900. PubMed ID: 24737380 [TBL] [Abstract][Full Text] [Related]
26. Targeting mTOR as a Therapeutic Approach in Medulloblastoma. Aldaregia J; Odriozola A; Matheu A; Garcia I Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29932116 [TBL] [Abstract][Full Text] [Related]
27. MK-4101, a Potent Inhibitor of the Hedgehog Pathway, Is Highly Active against Medulloblastoma and Basal Cell Carcinoma. Filocamo G; Brunetti M; Colaceci F; Sasso R; Tanori M; Pasquali E; Alfonsi R; Mancuso M; Saran A; Lahm A; Di Marcotullio L; Steinkühler C; Pazzaglia S Mol Cancer Ther; 2016 Jun; 15(6):1177-89. PubMed ID: 26960983 [TBL] [Abstract][Full Text] [Related]
28. Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma. Allen-Petersen BL; Risom T; Feng Z; Wang Z; Jenny ZP; Thoma MC; Pelz KR; Morton JP; Sansom OJ; Lopez CD; Sheppard B; Christensen DJ; Ohlmeyer M; Narla G; Sears RC Cancer Res; 2019 Jan; 79(1):209-219. PubMed ID: 30389701 [TBL] [Abstract][Full Text] [Related]
29. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects. Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615 [TBL] [Abstract][Full Text] [Related]
30. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279 [TBL] [Abstract][Full Text] [Related]
31. Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer. Enomoto K; Zhu X; Park S; Zhao L; Zhu YJ; Willingham MC; Qi J; Copland JA; Meltzer P; Cheng SY J Clin Endocrinol Metab; 2017 Jul; 102(7):2268-2280. PubMed ID: 28368473 [TBL] [Abstract][Full Text] [Related]
32. BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo. Shao Q; Kannan A; Lin Z; Stack BC; Suen JY; Gao L Cancer Res; 2014 Dec; 74(23):7090-102. PubMed ID: 25277525 [TBL] [Abstract][Full Text] [Related]
33. Deptor Is a Novel Target of Wnt/β-Catenin/c-Myc and Contributes to Colorectal Cancer Cell Growth. Wang Q; Zhou Y; Rychahou P; Harris JW; Zaytseva YY; Liu J; Wang C; Weiss HL; Liu C; Lee EY; Evers BM Cancer Res; 2018 Jun; 78(12):3163-3175. PubMed ID: 29666061 [TBL] [Abstract][Full Text] [Related]
34. Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma. Brun SN; Markant SL; Esparza LA; Garcia G; Terry D; Huang JM; Pavlyukov MS; Li XN; Grant GA; Crawford JR; Levy ML; Conway EM; Smith LH; Nakano I; Berezov A; Greene MI; Wang Q; Wechsler-Reya RJ Oncogene; 2015 Jul; 34(29):3770-9. PubMed ID: 25241898 [TBL] [Abstract][Full Text] [Related]
35. Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers. Bihani T; Ezell SA; Ladd B; Grosskurth SE; Mazzola AM; Pietras M; Reimer C; Zinda M; Fawell S; D'Cruz CM Oncotarget; 2015 Feb; 6(4):2407-20. PubMed ID: 25537515 [TBL] [Abstract][Full Text] [Related]
36. Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression. Thomas WD; Chen J; Gao YR; Cheung B; Koach J; Sekyere E; Norris MD; Haber M; Ellis T; Wainwright B; Marshall GM Oncogene; 2009 Apr; 28(13):1605-15. PubMed ID: 19234491 [TBL] [Abstract][Full Text] [Related]
37. Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3Kα inhibition in medulloblastoma. Eckerdt F; Clymer J; Bell JB; Beauchamp EM; Blyth GT; Goldman S; Platanias LC Sci Rep; 2019 Sep; 9(1):12822. PubMed ID: 31492956 [TBL] [Abstract][Full Text] [Related]
38. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Pourdehnad M; Truitt ML; Siddiqi IN; Ducker GS; Shokat KM; Ruggero D Proc Natl Acad Sci U S A; 2013 Jul; 110(29):11988-93. PubMed ID: 23803853 [TBL] [Abstract][Full Text] [Related]
39. Targeting MYC-driven replication stress in medulloblastoma with AZD1775 and gemcitabine. Moreira DC; Venkataraman S; Subramanian A; Desisto J; Balakrishnan I; Prince E; Pierce A; Griesinger A; Green A; Eberhardt CG; Foreman NK; Vibhakar R J Neurooncol; 2020 May; 147(3):531-545. PubMed ID: 32180106 [TBL] [Abstract][Full Text] [Related]
40. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents. Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]